JSC Grindeks Chairman of the Board Juris Bundulis: “To become patient-centric pharmaceutical industry representative in overall Group’s level, we are purposefully moving towards having a patient in the centre of our business. Our sustainable business model and the new commercial policy foresees continuous product range diversifying by implementing new, complex solutions to meet the needs of patients. Simultaneously, we are withdrawing products whose profitability and production volumes are low. In the first six months of 2019 we have improved the Group’s net profit margin and reached 7.65 million euro profit indicator which is a crucial step for further development. I anticipate that the Group’s turnover decrease is insignificant and will have a short-term effect.”

In the first six months of 2019, the Group’s production was exported to 68 countries worldwide, a total of 64.2 million euro, which is by 1.5 million euro or 2% less than in the first six months of 2018.

Grindeks sales volume of the final dosage forms in the first six months of 2019 was 63.0 million euro and it has decreased by 2.6 million euro in comparison to the first six months of 2018. In the first six months of 2019, the sales amount in Russia, the other CIS countries and Georgia reached 38.4 million euro, which is by 4.7 million euro or 11% less than in the first six months of 2018. In comparison to the first six months of 2018, in the first six months of 2019 the biggest increase in sales volume has been reached in Georgia (27%), Belarus (25%), Kirgizstan (24%), Armenia (18%) and Moldova (16%).

Sales volume of the final dosage forms in the EU countries in the first six months of 2019 reached 23.3 million euro which is by 2.1 million euro or 10% more than in the first six months of 2018. Sales volume of active pharmaceutical ingredients in the first six months of 2019 reached 5.1 million euro which is by 0.81 million euro or 19% more than in the first six months of 2018. During this reporting period Grindeks mostly exported its active pharmaceutical ingredients to the EU countries, Japan, Australia and Canada. The most required active pharmaceutical ingredients of “Grindeks” in the first six months of 2019 were dexmedetomidine, detomidine and oxytocin.